MeiraGTx (NASDAQ:MGTX – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for MeiraGTx and Immunocore, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 0 | 0 | 2 | 0 | 3.00 |
| Immunocore | 1 | 4 | 8 | 0 | 2.54 |
MeiraGTx presently has a consensus target price of $23.50, indicating a potential upside of 280.26%. Immunocore has a consensus target price of $65.64, indicating a potential upside of 103.46%. Given MeiraGTx’s stronger consensus rating and higher probable upside, equities research analysts plainly believe MeiraGTx is more favorable than Immunocore.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $14.02 million | 34.45 | -$84.03 million | ($1.21) | -5.11 |
| Immunocore | $249.43 million | 6.47 | -$55.29 million | ($0.95) | -33.96 |
Immunocore has higher revenue and earnings than MeiraGTx. Immunocore is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 8.4% of MeiraGTx shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
MeiraGTx has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Profitability
This table compares MeiraGTx and Immunocore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | -633.05% | -146.38% | -53.05% |
| Immunocore | -15.87% | -12.84% | -5.09% |
Summary
Immunocore beats MeiraGTx on 9 of the 14 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
